https://www.patientcareonline.com/view/idweek-2023-nirsevimab-efficacy-against-rsv-lrti-associated-hospitalization-is-robust-across-infant-subgroups
0
0
37 words
0
Comments
IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.
You are the first to view
Create an account or login to join the discussion